HSPG2 and acute myeloid leukemia: Similarly, distinguishing capacity of HSPG2 expression was also shown in non-M3 AML and cytogenetically normal AML patients (AUC = 0.888, 95% CI: 0.814–0.963, P < 0.001; AUC = 0.834, 95% CI: 0.719–0.949, P = 0.001; respectively; Fig. 3b, c).